Biocon-Viatris obtain USFDA nod for first interchangeable insulin
Research papers have highlighted that the US market witnessed an exponential increase in the prices of all insulins between 2002 and 2016. Biocon Biologics aims to improve access to affordable insulin for diabetes patients in the US market, as the company, with its partner Viatris, has received approval for Semglee (insulin glargine-yfgn injection) as the … Read more